New combo therapy may keep melanoma from coming back after surgery
NCT ID NCT04666272
First seen Feb 21, 2026 · Last updated May 23, 2026 · Updated 15 times
Summary
This study looks at whether taking two drugs, dabrafenib and trametinib, after surgery can help prevent melanoma from returning in Chinese patients with a specific gene change (BRAF V600). The treatment is given to people with stage III melanoma that has been completely removed. The main goal is to see how long patients stay cancer-free after starting the drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Fuzhou, Fujian, 350014, China
-
Novartis Investigative Site
Zhengzhou, Henan, 410100, China
-
Novartis Investigative Site
Wuhan, Hubei, 430022, China
-
Novartis Investigative Site
Changsha, Hunan, 410013, China
-
Novartis Investigative Site
Nanjing, Jiangsu, 210008, China
-
Novartis Investigative Site
Kunming, Yunnan, 650106, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310022, China
-
Novartis Investigative Site
Beijing, 100036, China
Conditions
Explore the condition pages connected to this study.